Capecitabine

CHEMBL1773 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
359.4 g/mol
LogP
0.6
Phase
4

An oral chemotherapy drug that is converted in the body, particularly in tumor tissue, to the active compound 5-fluorouracil, which inhibits cancer cell DNA synthesis. It is used to treat colorectal cancer, breast cancer, and gastric cancer. This prodrug approach allows oral administration while concentrating the active agent in tumors.

น้ำหนักโมเลกุล

359.3500 g/mol

LogP

0.60

TPSA

121.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F

InChI

InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

Molecular Formula

C15H22FN3O6

HBD / HBA

3 / 7

พันธะที่หมุนได้

7

อะตอมหนัก

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An oral chemotherapy drug that is converted in the body, particularly in tumor tissue, to the active compound 5-fluorouracil, which inhibits cancer cell DNA synthesis. It is used to treat colorectal cancer, breast cancer, and gastric cancer. This prodrug approach allows oral administration while concentrating the active agent in tumors.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Capecitabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1773. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 60953. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.